Drug Trials Snapshots: XOLREMDI (mavorixafor)

XOLREMDI is a prescription drug that increases the number of white blood cells released from the bone marrow into the blood. XOLREMDI is indicated for the treatment of adults and adolescents over the age of 12 years with WHIM (Warts, Hypogammaglobulinemia, Infection, and Myelokathexis) syndrome. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xolremdi